References
1. Ruccione KS, Wood JC, Sposto R, Malvar J, Chen C, Freyer DR.
Characterization of transfusion-derived iron deposition in childhood
cancer survivors. Cancer Epidemiol Biomarkers Prev 2014;23:1913-9.
2. de Ville de Goyet M, Moniotte S, Robert A, et al. Iron overload in
children undergoing cancer treatments. Pediatr Blood Cancer
2013;60:1982-7.
3. Sahlstedt L, von Bonsdorff L, Ebeling F, Parkkinen J, Juvonen E,
Ruutu T. Non-transferrin-bound iron in haematological patients during
chemotherapy and conditioning for autologous stem cell transplantation.
Eur J Haematol 2009;83:455-9.
4. Huang KE, Mittelman SD, Coates TD, Geffner ME, Wood JC. A significant
proportion of thalassemia major patients have adrenal insufficiency
detectable on provocative testing. J Pediatr Hematol Oncol 2015;37:54-9.
5. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological
and nonclinical studies investigating effects of iron in
carcinogenesis–a critical review. Crit Rev Oncol Hematol
2014;89:1-15.
6. Kuo DJ, Bhagia P. Incidentally Detected Transfusion-associated Iron
Overload in 3 Children After Cancer Chemotherapy. J Pediatr Hematol
Oncol 2018;40:e164-e6.
7. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions
in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
8. Rigoli L, Petrungaro A, Di Bella C, Caruso R. Iron overload and
malignancies in patients with haemoglobinopathies: A single center
experience. Transfus Apher Sci 2019;58:647-51.
9. Farmaki K, Tzoumari I, Pappa C. Oral chelators in
transfusion-dependent thalassemia major patients may prevent or reverse
iron overload complications. Blood Cells Mol Dis 2011;47:33-40.
10. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after
iron reduction in patients with peripheral arterial disease: results
from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
11. Coates TD. Physiology and pathophysiology of iron in
hemoglobin-associated diseases. Free radical biology & medicine
2014;72:23-40.
12. Coates TD, Wood JC. How we manage iron overload in sickle cell
patients. British journal of haematology 2017;177:703-16.
13. Kazak AE, Hocking MC, Ittenbach RF, et al. A revision of the
intensity of treatment rating scale: classifying the intensity of
pediatric cancer treatment. Pediatr Blood Cancer 2012;59:96-9.
14. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping
accurately estimates hepatic iron concentration in transfusion-dependent
thalassemia and sickle cell disease patients. Blood 2005;106:1460-5.
15. Wood JC. Guidelines for quantifying iron overload. Hematology Am Soc
Hematol Educ Program 2014;2014:210-5.
16. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive
measurement and imaging of liver iron concentrations using proton
magnetic resonance. Blood 2005;105:855-61.
17. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and
cardiac iron. Circulation 2011;123:1519-28.
18. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron
concentration and total body iron stores in thalassemia major. N Engl J
Med 2000;343:327-31.
19. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading
predicts cardiac iron loading in thalassemia major. Blood
2009;114:4021-6.
20. Wood JC. Estimating tissue iron burden: current status and future
prospects. British journal of haematology 2015;170:15-28.
21. Noetzli LJ, Panigrahy A, Hyderi A, Dongelyan A, Coates TD, Wood JC.
Pituitary iron and volume imaging in healthy controls. AJNR Am J
Neuroradiol 2012;33:259-65.
22. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and
volume predict hypogonadism in transfusional iron overload. American
journal of hematology 2012;87:167-71.
23. Coates TD. Iron overload in transfusion-dependent patients.
Hematology Am Soc Hematol Educ Program 2019;2019:337-44.
24. Ganz T. Systemic iron homeostasis. Physiological reviews
2013;93:1721-41.
25. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB.
Non-transferrin-bound iron induced by myeloablative chemotherapy.
British journal of haematology 1997;99:337-43.
26. Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T.
Non-transferrin-bound iron during allogeneic stem cell transplantation.
British journal of haematology 2001;113:836-8.
27. Ghugre NR, Coates TD, Nelson MD, Wood JC. Mechanisms of tissue-iron
relaxivity: nuclear magnetic resonance studies of human liver biopsy
specimens. Magn Reson Med 2005;54:1185-93.
28. Ghugre NR, Gonzalez-Gomez I, Butensky E, et al. Patterns of hepatic
iron distribution in patients with chronically transfused thalassemia
and sickle cell disease. American journal of hematology 2009;84:480-3.
29. Ghugre NR, Gonzalez-Gomez I, Shimada H, Coates TD, Wood JC.
Quantitative analysis and modelling of hepatic iron stores using
stereology and spatial statistics. Journal of microscopy
2010;238:265-74.
30. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance
for prediction of cardiac complications in thalassemia major.
Circulation 2009;120:1961-8.
31. Puliyel M, Mainous AG, 3rd, Berdoukas V, Coates TD. Iron toxicity
and its possible association with treatment of Cancer: lessons from
hemoglobinopathies and rare, transfusion-dependent anemias. Free radical
biology & medicine 2015;79:343-51.
32. Berdoukas V, Nord A, Carson S, et al. Tissue iron evaluation in
chronically transfused children shows significant levels of iron loading
at a very young age. American journal of hematology 2013;88:E283-5.
33. Garbowski MW, Cabantchik I, Hershko C, Hider R, Porter JB. The
clinical relevance of detectable plasma iron species in iron overload
states and subsequent to intravenous iron-carbohydrate administration.
American journal of hematology 2023;98:533-40.
34. Altes A, Remacha AF, Sarda P, Baiget M, Canals C, Sierra J. The
relationship between transferrin saturation and erythropoiesis during
stem cell transplantation. Haematologica 2006;91:992-3.
35. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC.
Pancreatic iron and glucose dysregulation in thalassemia major. American
journal of hematology 2012;87:155-60.
36. Tukenova M, Diallo I, Anderson H, et al. Second malignant neoplasms
in digestive organs after childhood cancer: a cohort-nested case-control
study. Int J Radiat Oncol Biol Phys 2012;82:e383-90.
37. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of
health outcomes among adults treated for childhood cancer. Jama
2013;309:2371-81.
38. Ruccione KS, Mudambi K, Sposto R, Fridey J, Ghazarossian S, Freyer
DR. Association of projected transfusional iron burden with treatment
intensity in childhood cancer survivors. Pediatr Blood Cancer
2012;59:697-702.
39. Łęcka M, Słomka A, Albrecht K, Żekanowska E, Romiszewski M,
Styczyński J. Unbalance in Iron Metabolism in Childhood Leukemia
Converges with Treatment Intensity: Biochemical and Clinical Analysis.
Cancers 2021;13.
40. Nottage K, Gurney JG, Smeltzer M, Castellanos M, Hudson MM, Hankins
JS. Trends in transfusion burden among long-term survivors of childhood
hematological malignancies. Leuk Lymphoma 2013;54:1719-23.
41. Puliyel M, Sposto R, Berdoukas VA, et al. Ferritin trends do not
predict changes in total body iron in patients with transfusional iron
overload. American journal of hematology 2014;89:391-4.
42. Taher AT, Porter JB, Viprakasit V, et al. Defining serum ferritin
thresholds to predict clinically relevant liver iron concentrations for
guiding deferasirox therapy when MRI is unavailable in patients with
non-transfusion-dependent thalassaemia. British journal of haematology
2015;168:284-90.
43. Wilson SR, Sears M, Williams E, et al. Gaps in the diagnosis and
management of iron overload in sickle cell disease: a ’real-world’
report from the GRNDaD registry. British journal of haematology 2021.
44. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology
2020 guidelines for sickle cell disease: transfusion support. Blood Adv
2020;4:327-55.
45. Ellervik C, Andersen HU, Tybjærg-Hansen A, et al. Total mortality by
elevated transferrin saturation in patients with diabetes. Diabetes Care
2013;36:2646-54.
46. Kremastinos DT, Farmakis D, Aessopos A, et al. Beta-thalassemia
cardiomyopathy: history, present considerations, and future
perspectives. Circulation Heart failure 2010;3:451-8.
47. Hodroj MH, Bou-Fakhredin R, Nour-Eldine W, Noureldine HA, Noureldine
MHA, Taher AT. Thalassemia and malignancy: An emerging concern? Blood
Rev 2019;37:100585.
48. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
Normalisation of total body iron load with very intensive combined
chelation reverses cardiac and endocrine complications of thalassaemia
major. British journal of haematology 2010;148:466-75.